Biodel Inc.


Company Update (NASDAQ:BIOD): Biodel Inc Reports Second Quarter Fiscal Year 2016 Financial Results

Biodel Inc (NASDAQ:BIOD) reported financial results for the second fiscal quarter ended March 31, 2016. “As we continue to diligently evaluate strategic alternatives to …

Stock Update (NASDAQ:BIOD): Biodel Inc Reports First Quarter Fiscal Year 2016 Financial Results

Biodel Inc (NASDAQ:BIOD) reported financial results for the first fiscal quarter ended December 31, 2015. Corporate updates since last fiscal quarter: In October 2015, …

Stock Update (NASDAQ:BIOD): Biodel Inc Announces Data Presentations at the Diabetes Technology Society Conference

Biodel Inc (NASDAQ:BIOD) will present data from studies of its ultra-rapid-acting prandial/basal insulin and Glucagon Emergency Management (GEM) product candidates during the Diabetes Technology …

Stock Update (NASDAQ:BIOD): Biodel Inc Announces Removal of Partial Clinical Hold for BIOD-531 and Plans for Potential Expansion of Target Patient Population

Biodel Inc (NASDAQ:BIOD) announced that the United States Food and Drug Administration (FDA) has removed the partial clinical hold for Biodel’s previously initiated Phase …

Company Update (NASDAQ:BIOD): Biodel Inc Reports Third Quarter Fiscal Year 2015 Financial Results

Biodel Inc (NASDAQ:BIOD) reported financial results for the third fiscal quarter ended June 30, 2015. Portfolio update since last fiscal quarter: Successful End-of-Phase 2 …

Company Update (NASDAQ:BIOD): Biodel Inc to Present Data on Concentrated Ultra-Rapid-Acting/Basal Insulin and Glucagon at the 75th American Diabetes Association Scientific Sessions

Biodel Inc (NASDAQ:BIOD) will present data from human and animal studies with its ultra-rapid-acting/basal insulin and glucagon product candidates during the 75th Scientific …

Stock Update (NASDAQ:BIOD): Biodel Inc Announces Phase 2b Clinical Trial Initiation of BIOD-531, the Company’s Concentrated, Ultra-Rapid-Acting, Prandial/Basal Combination Insulin Candidate

Biodel Inc (NASDAQ:BIOD) announced the initiation of a Phase 2b clinical trial of BIOD-531, the Company’s concentrated, proprietary, recombinant human insulin (RHI) based ultra-rapid-acting prandial/basal …

Stock Update (NASDAQ:BIOD): Biodel Inc Appoints Ms. Arlene M. Morris to Its Board of Directors

Biodel Inc (NASDAQ:BIOD) announced the appointment of Ms. Arlene M.

Company Update (NASDAQ:BIOD): Biodel Inc Reports Second Quarter Fiscal Year 2015 Financial Results

Biodel Inc (NASDAQ:BIOD) reported financial results for the second fiscal quarter ended March 31, 2015. Portfolio highlights since last fiscal quarter: Announced positive clinical …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts